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 1 
ABSTRACT 2 
Streptococcus suis is an emerging zoonotic pathogen. However, with the lack 3 
of an effective vaccine, antibiotics remain the main tool to fight against infections 4 
caused by this pathogen. We have previously observed a reserpine-sensitive 5 
fluoroquinolone-efflux phenotype in this species. Here, SatAB and SmrA, two 6 
pumps belonging to the ATP Binding Cassette and the Major Facilitator 7 
Superfamily respectively, have been analyzed in the fluoroquinolone-resistant 8 
clinical isolate BB1013. Genes encoding these pumps were overexpressed either 9 
constitutively or in the presence of ciprofloxacin in this strain. These genes could not 10 
be cloned onto plasmids in E. coli despite strong expression repression. Finally, site 11 
directed insertion of smrA and satAB in the amy locus of Bacillus subtilis 12 
chromosome using ligated PCR amplicons allowed for the functional expression and 13 
study of both pumps. Results showed that SatAB is a narrow spectrum 14 
fluoroquinolone exporter (norfloxacin and ciprofloxacin), susceptible to reserpine, 15 
whereas SmrA was not involved in fluoroquinolone extrusion. Chromosomal 16 
integration in Bacillus is a novel method for studying efflux pumps from Gram-17 
positive bacteria, which enabled us to demonstrate the implication of SatAB, and 18 
not of SmrA, in fluoroquinolone efflux in S. suis. 19 
 20 
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INTRODUCTION 1 
Streptococcus suis is a worldwide distributed zoonotic pathogen affecting pig and 2 
man (21). In industrialized countries it is mainly regarded as an important economic 3 
burden to the pig industry that only sporadically causes infections in humans. It is 4 
therefore defined as an occupational zoonosis with the main risk groups being people in 5 
close contact with pigs and pork. Nevertheless, cases of S. suis meningitis have also been 6 
reported in patients with no history of contact with live pigs or their products, and recent 7 
data suggest that S. suis could be a food borne disease (17, 21, 27). In several developing 8 
countries in South East Asia, S. suis is one of the main causes of meningitis in humans, 9 
even though its prevalence is probably still under-estimated (19, 22, 25, 40). Several 10 
outbreaks of S. suis have occurred in China (47). The largest outbreak took place during 11 
the summer of 2005 in Sichuan province, and affected 204 people causing 38 fatalities. 12 
Mortality was high as a result of the onset of a Streptococcal Toxic Shock Syndrome 13 
(STSS) similar to the one produced by Group A streptococci (GAS) (42). Consequently, 14 
concern about this pathogen has risen in these areas, and measures to prevent or hinder its 15 
impact are already being taken (19). 16 
Antimicrobial resistance is one of the most concerning phenomena in infectious 17 
diseases. In S. suis, resistance to neomycin, erythromycin, spiramycin, lincomycin, 18 
trimethoprim-sulphamethoxazole, and tetracycline antibiotics is a common feature (33, 19 
36, 46). Interestingly, genome comparison of STSS-producing strains has led to the 20 
discovery of ICESsuBM4072, a putative mobile Pathogenicity Island bearing tetracycline 21 
resistance determinants TetL and TetO, erythromycin ribosome methylase ErmB, a 22 
chloramphenicol acetyltransferase and a dihydrofolate reductase (18). The role played by 23 
  
4 
these genetic structures must not be overlooked, as it has been recently proved that 1 
Genomic Islands are prevalent in the genome of S. suis (48). Treatment of infections 2 
caused by S. suis remain, in general, effective by administration of beta-lactam 3 
antibiotics. Nevertheless, strains showing resistance to this family of drugs have been 4 
reported (14, 36). Fluoroquinolones are the main alternative to beta-lactam antibiotics for 5 
treatment of streptococcal infections (9). We have reported increasing fluoroquinolone 6 
(FQ) resistance among clinical S. suis isolates in Spain (8). Substitutions in the quinolone 7 
resistance determining regions (QRDR) of the genes encoding the antibiotic targets, gyrA 8 
and parC, were identified (8). Interestingly, the FQ-resistance phenotype could be 9 
partially reduced by the efflux pump inhibitor reserpine, indicating that efflux may be 10 
involved in FQ-resistance in S. suis. Several efflux pumps conferring resistance to 11 
fluoroquinolones have been described in other Gram-positive bacteria. Mainly members 12 
of two families of transporters are involved: (i) proteins belonging to the Major 13 
Facilitator Superfamily (MFS), such as Bmr of Bacillus subtilis (30), NorA of 14 
Staphylococcus aureus (43), Lde from Listeria monocytogenes (13), and PmrA in 15 
Streptococcus pneumoniae (12); and (ii) exporters belonging to the vast ATP Binding 16 
Cassette (ABC) family, such as PatA and PatB from S. pneumoniae (29) or LmrA from 17 
Lactococcus lactis (44). Efflux-mediated drug resistance is normally a consequence of 18 
overexpression of the genes encoding the pumps, either through mutations in regulators 19 
or in promoter regions thereof (31). Amino acid substitutions can also lead to resistance 20 
through a change in the substrate recognition of the pump (32, 34).  21 
To date, no FQ efflux pumps have been described in S. suis. Here we report the 22 
implication of SatAB, an ABC transporter homologous to PatA and PatB, in resistance to 23 
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ciprofloxacin and norfloxacin in S. suis. Further, intensive study of SmrA, a Major 1 
Facilitator Superfamily transporter analogous to pneumococcal FQ-efflux pump PmrA, 2 
allows for neglecting its role in FQ-resistance. Study of these pumps was accomplished 3 
with a knock-in strategy, integrating the genes encoding the pumps in monocopy in the 4 
chromosome of Bacillus subtilis 168 under the control of an inducible promoter. This 5 
system has proven to be a promising tool for the study of efflux pumps in Gram-positive 6 
bacteria. 7 
 8 
MATERIALS AND METHODS 9 
Bacterial strains, culture conditions and susceptibility testing 10 
The characteristics of the strains and plasmids used in this study are listed in 11 
Table 1. B. subtilis 168 and pDR67 were kindly donated by Tarek Msadek from Institut 12 
Pasteur in Paris.  13 
S. suis and S. pneumoniae strains were cultured on Columbia sheep blood agar 14 
plates, Todd-Hewitt broth and a casein hydrolysate-based medium with 0.3% sucrose 15 
(AGCH) as energy source. B. subtilis 168 was cultured on LB agar or in LB broth. Media 16 
were supplemented with chloramphenicol to a final concentration of 5 µg/ml and 2.5 17 
µg/ml for B. subtilis and S. pneumoniae transformants respectively. Culture media were 18 
obtained from Oxoid (Oxoid Ltd., Basingstoke, United Kingdom) and Biomérieux 19 
(BioMérieux, France). Chemicals, additives and antibiotics were supplied by Merck 20 
(Merck KGaA, Darmstadt, Germany) and Sigma-Aldrich (Sigma Chemical Co. St Louis, 21 
Mo). IPTG was purchased from Invitrogen (Invitrogen, Carlsbad, CA).  22 
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Susceptibility tests were carried out following CLSI guidelines (6). Efflux 1 
phenotype visualization was performed by adding 40 µg of ciprofloxacin, enrofloxacin 2 
and levofloxacin, and 100 µg of norfloxacin, in 10 µl volume, to non-impregnated discs 3 
that were used for diffusion antibiograms on standard media with and without 10 µg/ml 4 
of reserpine dissolved in acetone. Non-impregnated and antibiotic discs were obtained 5 
from Biomerieux (BioMérieux, France) and Oxoid (Oxoid Ltd., Basingstoke, United 6 
Kingdom). For sugar assays, API 50CH were obtained from Biomérieux and used 7 
following manufacturer’s instructions. 8 
DNA analysis and manipulation 9 
Primers used in this study were supplied by Roche (Roche, Germany), and Sigma-10 
Genosys (Sigma Chemical Co. St Louis, Mo). A list of the primers used can be found in 11 
Table 2. PCRs were performed using Taq Polymerase from Biotools (B&M Labs, Spain). 12 
Phusion polymerase (Finnzymes, Woburn, MA) was used for the obtention of long 13 
amplicons. pCR2.1 and pBAD plasmids and E. coli IncF’ (Top10) strain were purchased 14 
from Invitrogen (Invitrogen, Carlsbad, CA). Plasmid DNA extraction and purification of 15 
PCR fragments were performed as previously described (37). For plasmid extraction 16 
from S. pneumoniae and S. suis a modified first step with sodium deoxycholate was used 17 
as previously described (39). Automated sequencing was carried out at Secugen S. L. 18 
(Madrid, Spain). Sequence analysis was performed using DNA Strider 1.4f13 (CEA, 19 
France), 4Peaks 1.6 (Mek&Tosj, Netherlands), CLC DNA Workbench Software 20 
(Denmark), ClustalW, NEBCutter (45) and NIH online analysis tools 21 
(http://www.ncbi.nlm.nih.gov). Promoter sequence analysis was performed with Bprom 22 
(Softberry Inc. Mount Kisco, NY). Protein modeling was done using Phyre server (24), 23 
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and illustrated using PyMol Molecular Graphics System, (Version 1.3, Schrödinger, 1 
LLC.). 2 
RNA extraction and RT-PCR 3 
RNA from all strains was obtained from liquid cultures in early exponential phase 4 
(DO600=0.3). When ciprofloxacin was added to the culture media, concentrations used 5 
were ¼ of the MIC of each strain. RNA extractions were performed twice from each 6 
strain and condition using RNA-easy Kit (Qiagen, Inc., Chatworth, California, USA). 7 
Digestions with DNase were performed following manufacturers instructions. Absence of 8 
DNA was checked through PCR. Several digestions were performed until PCR results 9 
obtained were negative. cDNA was obtained using Superscript III retrotranscriptase 10 
(Invitrogen, Carlsbad, CA) and 6bp random primers. Presence of cDNA was confirmed 11 
with conventional PCR. RT-PCR primers (Table 2) were designed using Allele ID 7.7 12 
software (Premier Biosoft, Palo Alto, CA). Q-PCR was carried out in triplicates using 13 
MyiQ thermal cycler (Bio-Rad Laboratories Inc. Spain). Every condition and strain was 14 
tested three times. No primer dimer was obtained in any of the PCRs. Efficiency of all 15 
assays was 100% ± 5%. Results on the expression of smrA and satAB were normalized 16 
using rpoB. Primers rpoB428 and rpoB468R, targeting the rpoB gene of S. pneumoniae, 17 
have been previously described (4). 18 
Cloning of smrA and satAB in B. subtilis chromosome  19 
In order to clone smrA and satAB in pDR67, XbaI and BglII restriction sites were 20 
used. Amplification of the ORFs including their putative RBSs was carried out using 21 
primers designed to bear both restriction sites (Table 2). Plasmid and inserts were 22 
digested using XbaI and BglII (Takara Bio, Inc., Japan) and ligated using T4 DNA ligase 23 
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(New England Biolabs, Beverley, MA). The ligation product was directly transformed in 1 
B. subtilis using a two-step transformation procedure as previously described (15). 2 
Colonies were phenotypically tested for pDR67 integration in the chromosome. Briefly, 3 
amyE disruption leads to the loss of alpha amylase activity. This can be evidenced by 4 
growth on 1% potato starch and staining with iodine pearls. Clones not showing a light 5 
halo around the colonies were selected, for its amylase activity was lost, presumably 6 
because of pDR67 integration. These observations were confirmed by PCR and 7 
sequencing. 8 
Mobilization of the expression system bearing smrA to pJS3 9 
Streptococcal plasmid pJS3 was amplified by PCR with primers bearing EcoRI 10 
and BamHI restriction sites located close together and facing outwards (Table 2). The 11 
product was phosphorylated using polinucleotide kinase, ligated using T4 DNA ligase 12 
and transformed in S. pneumoniae R6 as previously described (26). The resulting plasmid 13 
was called pJS3EB and bore both restriction sites plus a new unique NdeI site in between. 14 
Pspac-lacI and Pspac-smrA-lacI from strains BB1066 and BB1067 respectively, were 15 
amplified using primers with EcoRI and BamHI restriction sites (Table 2). Both inserts 16 
and pJS3EB were digested using EcoRI and BamHI and ligated with T4 DNA ligase. All 17 
enzymes were purchased from New England Biolabs (New England Biolabs, Beverley, 18 
MA). 19 
Influence of pH in the activity of SmrA 20 
LB was used as growth media and pH was adjusted to 5, 6, 7 and 8 adding HCl or 21 
NaOH after autoclaving. Inocula were adjusted to 0.5 MacFarland and diluted 1:200 in 22 
the growth medium. IPTG was added to a final concentration of 1mM. Ciprofloxacin and 23 
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norfloxacin were tested covering a wide range of concentrations from subinhibitory to 1 
inhibitory (0.02 to 0.3 µg/ml for ciprofloxacin and from 0.06 to 0.8 µg/ml for 2 
norfloxacin). Growth curves were performed in a Tecan Infinite 200 apparatus (Tecan 3 
Group Ltd. Männendorf Switzerland). 24-well plates were incubated at 37ºC and OD620 4 
measurements were taken every 10 minutes after 15 seconds shaking with 2.5 mm 5 
amplitude. 6 
Biolog 7 
Phenotypic MicroArrays (Biolog, Hayward, CA) were performed at the Animal 8 
Health and Veterinary Laboratories Agency, Weybridge, UK. Strains were cultured on 9 
agar plates under selective pressure as described above. Cell suspensions were prepared 10 
as previously described (2) to directly obtain an 81% transmittance (T). All inoculating 11 
fluids were purchased from Biolog Inc. Inocula were prepared following manufacturer’s 12 
instructions and IPTG was added to a final concentration of 1 mM for B. subtilis and 0.5 13 
mM for S. pneumoniae. Microarray plates were incubated at 37ºC and colorimetric 14 
readings were performed at 15 minute intervals over a 48h period using the OmniLog 15 
reader. Kinetic data were analyzed using the OmniLog PM software (Biolog). Phenotypic 16 
Microarrays used for both B. subtilis and S. pneumoniae strains included PM1 and 2A for 17 
carbon pathways, and PM11A to 20B for sensitivity to 240 chemicals at 4 different 18 
concentrations. Furthermore S. pneumoniae strains were also tested against panels PM9 19 
and 10 for ion/osmotic effects and pH respectively. All assays were performed on at least 20 
two separate occasions. 21 
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Nucleotide sequence accession numbers 1 
The nucleotide sequences of this study have been deposited in GenBank under the 2 
following accession numbers: smrA, including the promoter region, in BB1001, 3 
JF416696; in BB1002, JF416694; and in BB1013, JF416698; and satRAB in BB1001, 4 
JF416697; in BB1002, JF416695; and in BB1013, JF416699.5 
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RESULTS 1 
Efflux is involved in FQ resistance in S. suis 2 
In our previous work S. suis, isolates of animal origin showing high level FQ 3 
resistance were studied (8). These isolates carried resistance mutations in the quinolone 4 
resistance determining regions (QRDR) of gyrA and parC, genes encoding the antibiotic 5 
targets. In order to assess the involvement of drug efflux in the FQ-resistance phenotype, 6 
ciprofloxacin MIC were determined with and without the efflux pump inhibitor reserpine. 7 
In all but one resistant isolates, resistance levels were 2 to 4-fold lower in the presence of 8 
reserpine, indicating that efflux was involved in FQ-resistance in these strains. No 9 
decrease in the MIC was observed in any of the FQ-susceptible strains in presence of 10 
reserpine. To unequivocally prove these results, a diffusion antibiogram method that 11 
enabled a clear visualization of the efflux phenotype was developed. Custom made 12 
antibiogram discs, bearing high concentrations of various fluoroquinolones, were used on 13 
standard media with and without reserpine against BB1013, an isolate with ciprofloxacin 14 
MICs of 64 and 16 μg/ml in the absence and presence of reserpine, respectively, known 15 
to also carry ParC Ser79Tyr and GyrA Ser81Lys changes involved in FQ-resistance (8). 16 
Clear growth-inhibition zones were obtained to ciprofloxacin and norfloxacin only when 17 
reserpine was added, showing the existence of reserpine-sensitive FQ-efflux. However, 18 
resistance to enrofloxacin and levofloxacin was unaffected by reserpine (Figure 1). 19 
 20 
Identification of smrA and satAB 21 
Three FQ efflux pumps have been widely studied in the close member of the 22 
genus S. pneumoniae. PmrA, first described as a norfloxacin extruder (12), is an MFS 23 
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transporter, whereas PatA and PatB are ABC transporters involved in ciprofloxacin and 1 
norfloxacin efflux among other compounds (29). We searched for homologues of these 2 
pumps in the available S. suis genomes, in order to study their possible implication in FQ 3 
resistance in this species. 4 
smrA: an ORF encoding a predicted protein showing a 58% identity with PmrA 5 
was found in the genome of S. suis and named smrA. The genetic environment of smrA 6 
was analogous to that of pmrA (Figure 2). Protein modeling of the 401 amino acid-long 7 
product, SmrA, revealed a 12 transmembrane segments structure found in most MFS 8 
transporters (Figure 3). The complete gene sequence with the corresponding promoter 9 
region was obtained from resistant strain BB1013 and from the two susceptible, 10 
genetically unrelated, clinical isolates BB1001, and BB1002 (8). SmrA of BB1013 11 
presented two residue substitutions (Thr107Ala and Ile126Val) when compared to the 12 
susceptible alleles, which were identical between each other (Figure 3). The promoter 13 
region of smrA presented a canonical -35 box (TTGACAA) and Ribosome Binding Site 14 
(RBS) (GGAGG) at positions -66 and -14 (Figure 2). No -10 box was identified. 15 
Interestingly, between the -35 box and the region where the -10 box should be located, a 16 
7-bp inverted repeat, separated by 5 bp, was found. When any 2 of the 5 bp are erased in 17 
silico a sequence resembling a -10 box is found immediately after the 3’ repeat, 18 
suggesting smrA could be regulated the way bmr is (16). Briefly, expression of bmr is 19 
controlled by BmrR that binds to a dyad symmetry region in its promoter sequence and 20 
brings the -10 box 2 bp closer to the -35 box, to an optimal 17 bp distance. Interestingly, 21 
a mutation in the 3’ inverted repeat was found in the sequence of the resistant strain 22 
suggesting a possible deregulation of smrA in BB1013. Further experiments were focused 23 
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on elucidating whether overexpression of smrA or/and the amino acidic substitutions 1 
found in SmrABB1013 could be involved in fluoroquinolone resistance in BB1013. 2 
satA and satB: two homologues of pneumococcal FQ-efflux pumps PatA and 3 
PatB, showing 66% and 67% identity, were identified in S. suis genomes and named SatA 4 
and SatB. Protein modeling revealed an N-terminal transmembrane domain and a C-5 
terminal nucleotide binding domain structure characteristic of ABC transporters (Figure 6 
3). Interestingly, in contrast to the pneumococcal organization of the ORFs, in wich these 7 
genes seem to be independently cotranscribed, satA and satB showed in S. suis a classical 8 
operon conformation, with both genes immediately contiguous on the same strand and 9 
reading frame (Figure 2). Furthermore, upstream satA and partly overlapping with it, an 10 
ORF coding for a regulator of the MarR family was found and named satR. To determine 11 
if satA and satB were cotranscribed on the same mRNA a PCR from one gene to the 12 
other, using primers SatAIntF and SatBIntR (Table 2) was performed on cDNA from 13 
BB1001 and BB1013. A 2 kb fragment was amplified from the cDNA and the control 14 
DNA of the two strains, proving the suspected operon conformation of both ORFs (data 15 
not shown). This organization points to the function of SatA and SatB being intimately 16 
related and is in accordance to other authors suggestion of a heterodimeric SatAB 17 
transporter (11). Primers satAF and satBR, amplifying the whole operon and its regulator, 18 
were designed using the available S. suis genomes in GenBank. The sequences of satR 19 
and satAB of BB1001, BB1002 and BB1013 were obtained by primer walking and 20 
analyzed. Several amino acid differences, mainly located in the transmembrane segments, 21 
were found among the three alleles of both genes (Figure 2). Interestingly, sequence 22 
analysis of the putative regulator SatR revealed in BB1013 a C238T mutation leading to a 23 
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premature stop codon (CAA80TAA) compared to BB1001, BB1002 and GenBank 1 
sequences.  2 
 3 
Expression analysis 4 
Efflux pumps can lead to antimicrobial resistance through overexpression. In 5 
order to assess if smrA and satAB were overexpressed in BB1013, the levels of mRNA of 6 
these pumps were measured by means of RT-Q-PCR using BB1001 as a control (Figure 7 
4). 8 
Expression of smrA was not significantly different between BB1013 and the 9 
control strain in the absence of fluoroquinolones. When subinhibitory concentrations of 10 
ciprofloxacin were added to the culture medium, to a final concentration of ¼ of the MIC 11 
(0,12 μg/ml for BB1001 and 16 μg/ml for BB1013), BB1013 increased the levels of 12 
expression of smrA, leading to a significant four-fold difference between both strains.  13 
Expression of satAB was found to be about fifteen times higher in BB1013 than in 14 
the control strain in the absence of ciprofloxacin. Interestingly, expression was not 15 
enhanced, but mildly repressed by the presence of ciprofloxacin in the culture media.  16 
Expression analysis showed that both pumps were overexpressed in BB1013, 17 
either under induction by ciprofloxacin, as is the case of SmrA, or constitutively as for 18 
SatAB. Moreover, these data suggest that SatR acts as a repressor of satAB in S. suis. 19 
 20 
Cloning and expression of smrA and satAB in B. subtilis  21 
Cloning of satAB and smrA in E. coli, as performed successfully with other pumps 22 
such as NorA or Bmr (30, 43), was investigated. Despite repeated attempts, the genes 23 
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encoding the putative pumps could not be cloned in pCR2.1 plasmid and transformed into 1 
an E. coli IncF’ strain. Thus, cloning under the control of pBAD promoter was tested. 2 
Although repression was enhanced by the addition of G-6-P (glucose-6-phosphate) and 3 
fucose, cloning of S. suis efflux pumps was unsuccessful in all cases, suggesting a high 4 
toxicity of the insert in a Gram-negative environment. Thus, cloning in B. subtilis was 5 
explored as an alternative strategy. 6 
pDR67 (23) is a plasmid capable of replicating in E. coli and integrating in 7 
Bacillus subtilis chromosome. It is designed for cloning inserts under the control of the 8 
IPTG-inducible promoter Pspac. Expression is tightly repressed by the presence, 9 
downstream the insert, of the promoter’s operator, lacI. Furthermore, repression can be 10 
strengthened using lacIq E. coli strains (such as XL1-Blue). pDR67 bears two homology 11 
regions with the non-essential amyE chromosomal gene of B. subtilis, as well as a 12 
chloramphenicol marker suitable for selection in this species. It can therefore be used for 13 
mobilizing constructions obtained in E. coli to a Gram-positive environment as a single 14 
copy in the chromosome. IPTG induction is also feasible in this bacterium. 15 
smrA and satAB were cloned with their corresponding RBS in pDR67 and 16 
transformed in XL1-Blue E. coli. Despite the high levels of repression of the insert, 17 
transformation efficiency was low (data not shown). Furthermore, growth of 18 
transformants was evidently impaired and, when streaking these colonies onto new plates, 19 
various morphologies were recognizable. These clones did not seem to be suitable and 20 
were not used for further study. Interestingly, for each pump, one colony was found to be 21 
positive to the insert by PCR but did not display toxicity signs. Sequencing revealed 22 
premature stop codons in both inserts suggesting the non-functionality of the pumps as 23 
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the reason for the absence of toxicity (satA CAG→TAG in the case of satAB operon, and 1 
a deletion of A1008 in smrA leading to a frame shift altering the protein sequence of the 2 
following 15 amino acids and a CTA→TAG premature stop codon). These strains were 3 
used as controls when needed. Altogether, our data suggest that a cloning procedure 4 
including a passage of smrA and satAB through E. coli is unfeasible. Thus, the ligation 5 
products of satAB from the three strains (BB1001, BB1002 and BB1013) and smrA from 6 
BB1013 with pDR67 were directly transformed into B. subtilis 168 (Figure 5). Strains 7 
BB1068, B1069 and BB1070 bearing the three different alleles of satAB and BB1067 8 
bearing smrA from BB1013, were obtained (Table 1). Sequencing confirmed that the 9 
inserts harbored no mutations affecting the protein sequence. A transformant with the 10 
complete cloning system but no insert, namely BB1066, was obtained and conserved as a 11 
control. Last, plasmid pDR67 bearing a non-functional copy of satABBB1002 obtained in E. 12 
coli was also transformed in B. subtilis, giving rise to BB1071, a strain bearing the whole 13 
operon but with an interrupted satA gene.  14 
satAB confers resistance to fluoroquinolones. smrA does not 15 
smrA: Strain BB1067, bearing smrABB1013, was subjected to antimicrobial 16 
susceptibility testing using a wide variety of compounds. Strain BB1066 was used as a 17 
control. No differences were observed for any of the antibiotics and toxics tested. Primer 18 
walking confirmed the correct sequence of the insert. RT-PCR was also performed to 19 
confirm the induction of the system in this strain (data not shown). As MFS transporters 20 
obtain their energy from the proton gradient between the periplasm and the cytoplasm, 21 
we investigated whether pH of the medium could play a role in the activity of SmrA 22 
against fluoroquinolones. Growth curves in LB medium at pH 5, 6, 7 and 8 were 23 
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performed. Several norfloxacin and ciprofloxacin concentrations, ranging from 1 
subinhibitory to inhibitory, were tested in all pHs in presence of 1mM of IPTG. No 2 
significant difference could be observed when comparing BB1066 and BB1067 in any 3 
condition (data not shown). Therefore, our data suggest that smrA is not involved in 4 
fluoroquinolone resistance in S. suis. MFS transporters have also been described as sugar 5 
transporters (28). To test whether smrA could be involved in carbohydrate import or 6 
export API 50CH strips were inoculated with BB1067 with and without induction and 7 
compared to BB1066. No differences were observed among strains nor conditions, 8 
suggesting that SmrA is not a carbohydrate pump either. In order to determine the natural 9 
substrate of smrA, our strains were tested using Biolog phenotypic microarrays (PM). 10 
This high through-put technology facilitated the rapid testing of a wide variety of 11 
compounds. A panel of 240 antibiotics and toxic molecules at four different 12 
concentrations were tested on BB1067 under induction conditions, using BB1066 as the 13 
control strain. Strikingly, of all the set of molecules, BB1067 only showed a slight 14 
improvement of respiration in one of the dilutions of minocycline, a drug belonging to the 15 
family of tetracyclines (data not shown). Interestingly minocycline is generally not 16 
considered to be a substrate of MFS pumps except for the case of TetB (7). Biolog panel 17 
of carbon pathways was also tested confirming previous results on sugar usage and 18 
adding other compounds to SmrA’s list of non-substrate molecules.   19 
In order to rule out the possibility of SmrA not being active in B. subtilis the 20 
construction, from Pspac to lacI (see Figure 5), was mobilized to Streptococcus 21 
pneumoniae R6, a close member of the genus. pJS3, a plasmid derived from streptococcal 22 
native plasmid pMV158 (3), was modified to bear EcoRI and BamHI restriction sites and 23 
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named pJS3EB. The constructions in the chromosome of B. subtilis were amplified by 1 
PCR and cloned in pJS3EB using the new restriction sites, giving rise to plasmids 2 
pB1011, containing the empty system (Pspac-lacI) as in BB1066, and pB1012 with the 3 
system and smrABB1013 (Pspac-smrA-lacI), as in BB1067. Strains BB1072, and BB1073 4 
(Table 1) were obtained by transformation of pB1011 and pB1012 respectively into S. 5 
pneumoniae R6 (see materials and methods). Sequence of the insert was checked by PCR 6 
and sequencing. RT-PCR was performed in order to confirm that Pspac was inducible by 7 
IPTG in S. pneumoniae. Strains BB1072 and BB1073 were confronted to Biolog PM 8 
panel of antibiotics, carbohydrates and ion/osmotic effects, and the results confirmed 9 
previous observations on minocycline, proving B. subtilis to be a suitable model for the 10 
study of streptococcal MFS pumps. The natural substrate of this pump remains, though, 11 
elusive.   12 
satAB: Antimicrobial susceptibility testing to a wide variety of antimicrobials of 13 
strains bearing the three alleles of satAB was performed (data not shown). When IPTG 14 
was added to the culture media to a final concentration of 1mM, strains bearing a 15 
functional copy of satAB showed a decrease in susceptibility to norfloxacin and 16 
ciprofloxacin but not to levofloxacin, enrofloxacin, moxifloxacin, or nalidixic acid (Table 17 
3). In order to quantitate the effect of SatAB, MICs to ciprofloxacin and norfloxacin were 18 
determined with and without IPTG induction. All alleles conferred at least a four-fold 19 
decrease in susceptibility to both antibiotics. Interestingly, the allele originating from 20 
BB1002 conferred an extra doubling-dilution increase in resistance (up to eight-fold) 21 
against norfloxacin, and the allele from BB1013 did so to both norfloxacin and 22 
ciprofloxacin. These observations point to the diversity in amino acid composition of the 23 
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three alleles of SatAB as a possible factor in the levels of resistance observed, through 1 
modifications in the affinity for the drug. The addition of reserpine to the medium 2 
reverted the resistance phenotype. No differences were observed between strain BB1066 3 
bearing the expression system but no insert, and BB1071, bearing Δ satABBB1002 4 
confirming the non-functionality of the mutated insert. Fluoroquinolone efflux was only 5 
detected in presence of IPTG proving the system’s tight regulation (Table 2). No other 6 
fluoroquinolone tested was a substrate of satAB, nor were any of the antibiotics belonging 7 
to a variety of other families that were tested (data not shown). SatAB is therefore a 8 
narrow spectrum pump of norfloxacin and ciprofloxacin.  9 
  
20 
DISCUSSION 1 
Antimicrobial resistance is a major threat in the treatment of infectious diseases. 2 
Efflux is a worrying mechanism of resistance as efflux pumps are proteins involved in 3 
many basic life functions, such as osmoregulation or detoxification, and are hence 4 
ubiquitous in bacteria. Furthermore, efflux pumps often confer resistance to a wide array 5 
of unrelated compounds, allowing for a one-step selection of multi-resistant clones as 6 
well as for an undesirable co-selection phenomenon.  7 
Here we present SatAB, an efflux pump involved in fluoroquinolone resistance in 8 
S. suis. We also assessed the involvement of SmrA, an MFS transporter homologous to 9 
FQ-efflux pump PmrA, in this phenotype. Our data show that SatAB but not SmrA is 10 
involved in fluoroquinolone efflux in S. suis.  11 
Expression analysis of both pumps has been performed in clinical isolate BB1013. 12 
In the case of satAB, overexpression was constitutive, probably as a consequence of the 13 
loss of function of SatR due to a premature stop codon in its coding sequence. The 14 
expression of smrA was not significantly different from that of susceptible strain BB1001 15 
in the absence of antibiotic. Nevertheless, when sub-inhibitory concentrations of 16 
ciprofloxacin were added to the media, smrA was significantly overexpressed in BB1013 17 
as compared to BB1001, while satAB levels of expression remained stably high. 18 
Overexpression of efflux pumps in the presence of ciprofloxacin has already been 19 
observed for transporters not related to the efflux of this drug (29). Therefore, the link 20 
between expression and resistance is not concluding. Genetic approaches, such as knock-21 
out or knock-in mutants, are needed to confirm the implication of a pump in a given 22 
resistance phenotype. Cloning in E. coli is an easy and convenient approach for studying 23 
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gene function. Interestingly, some MFS pumps from Gram-positive bacteria, such as 1 
NorA or Bmr, have been cloned and are functional in E. coli (30, 43), while others, such 2 
as PmrA, have, to our knowledge, never been cloned in a Gram-negative species, despite 3 
the interest this pump raises. Altogether our data suggest that smrA and satAB are 4 
extremely toxic for E. coli. We hypothesize that a cell wall destabilization due to 5 
structural differences between E. coli and S. suis, is at the basis of this phenomenon. It 6 
would be interesting to elucidate the features that make some Gram-positive MFS pumps, 7 
and not others, toxic in Gram-negative bacteria even though they all share the same basic 8 
12-transmembrane segments structure. When cloning toxicity is an impediment, knock-9 
out mutants are the main strategy to study and characterize pumps. Nevertheless, tools to 10 
perform these assays have not been developed for all species. Even when available, wild 11 
type strains are often difficult to manipulate, and modifiable laboratory strains might not 12 
show the desired efflux phenotype. In S. suis, although some genetic tools are available 13 
(38), DNA transformation in BB1013 was found to be a bottleneck for further 14 
experiments. SmrA and SatAB were found to be very toxic in E. coli rendering the 15 
cloning and further study unviable in this species. Thus, a system enabling the 16 
introduction of SmrA and SatAB pumps, while avoiding toxicity, was required. pDR67 17 
and B. subtilis 168 were used to effectively obtain knock-in mutants that were suitable for 18 
studying efflux pumps. This system has proven to be a fast, easy and reliable tool in the 19 
study of MFS and ABC transporters of S. suis, and will surely be helpful for the study of 20 
other pumps from different Gram-positive species.  21 
PmrA is an MFS efflux pump from S. pneumoniae that has been, at least for some 22 
time, considered to be the main norfloxacin exporter in this bacterium. Since its first 23 
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description (12) PmrA has generally failed to be further related to FQ resistance in either 1 
wild type strains or laboratory mutants (1, 5, 29, 35). Its role in fluoroquinolone 2 
resistance remains therefore unclear and is now questioned. The function of SmrA, the 3 
homolog of pneumococcal PmrA in S. suis, was intensively studied. Our results point to 4 
SmrA as not being involved in fluoroquinolone resistance in BB1013. Among more than 5 
450 compounds tested, only minocycline, an antibiotic from the family of tetracyclines, 6 
seemed to be affected by SmrA. These differences were subtle and further investigations 7 
are needed to define the possible clinical impact of SmrA in minocycline resistance. 8 
Nevertheless they were consistent in genetic constructions both in B. subtilis and S. 9 
pneumoniae bearing an inducible copy of the pump, allowing the inference that the whole 10 
expression system works not only for ABC, but for MFS transporters too. Also, S. 11 
pneumoniae seems a suitable species for the use of Pspac-lacI expression system.  12 
Expression levels of smrA where measured in BB1013. Interestingly, expression 13 
of smrA increased in this strain in the presence of ciprofloxacin. As mentioned above, 14 
similar results have also been observed in S. pneumoniae for other transporters that are 15 
not involved in FQ extrusion (29). S. pneumoniae’s chromosome has been shown to be 16 
organized in topology-reacting gene clusters. DNA relaxation by a gyrase inhibitor 17 
modified global gene expression, which affected both pmrA (downregulation) and patA-18 
patB (up-regulation) in opposite ways (10). It would be relevant, from both a clinical and 19 
a basic research perspective, to elucidate the reasons why a subset of unrelated 20 
transporters are overexpressed when in presence of antibiotics that are not a substrate 21 
thereof. Unraveling whether this is a general response to FQ-induced stress, such as an 22 
increased superoxide production, or an indirect consequence of the effect of these 23 
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antibiotics on the coiling and topology of the chromosome (10), could be important for 1 
antimicrobial therapy.  2 
Our results prove that SatAB can extrude the fluoroquinolones norfloxacin and 3 
ciprofloxacin. Interestingly the alleles from both susceptible and resistant strains 4 
increased the levels of resistance to fluoroquinolones when cloned in B. subtilis. The 5 
activity of SatAB was partially reverted by reserpine, as was the case for BB1013. 6 
Interestingly, the MIC of susceptible S. suis strains was unaffected by reserpine (8), 7 
suggesting that the effect of this pump in the intrinsic levels of FQ-resistance in S. suis is 8 
probably low. It is unlikely that the natural function of SatAB is FQ efflux as these 9 
antibiotics are fully synthetic. Therefore, other functions of this transporter are yet to be 10 
unveiled. The genetic environment of satAB (Figure 2) (20) and the presence of SatA and 11 
SatB homologues in other streptococci (Figure 6), point to a possible implication in basic 12 
metabolic functions. Also, the phylogenetic relation of both genes with their homologues 13 
show a clear species-dependent clustering, suggesting that satAB co-evolves with the 14 
whole bacterial genome, and has not yet been the subject of horizontal gene transfer 15 
events.  16 
Interestingly, levels of resistance conferred by SatAB differed depending on the 17 
allele. A possible influence of the amino acid differences found among alleles cannot be 18 
ruled out. Still, SatAB overexpression seems to be the main requisite to obtain 19 
fluoroquinolone efflux. As it is the case for other pumps, of all fluoroquinolones tested, 20 
only ciprofloxacin and norfloxacin were affected by SatAB. This is interesting from both 21 
a drug-development and a structural point of view as the substrate ciprofloxacin and the 22 
non-substrate enrofloxacin only differ in a methyl group. An increased bulkiness of the 23 
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methylated substituent in position C7, that would impede enrofloxacin from traversing 1 
the pump’s channel, is likely to be at the basis of these differences (41). It is also relevant 2 
from a therapeutic perspective, as selection of efflux or gyrA/parC mutants could depend 3 
on the molecule used for treatment. 4 
Altogether our data on SmrA allows neglecting the possibility of it being a 5 
fluoroquinolone efflux pump of clinical relevance. Therefore, in order to further 6 
investigate S. suis mechanisms of FQ-resistance efforts should be directed to characterize 7 
in depth SatAB and the discovery of other possible transporters. Experiments to elucidate 8 
the implication of SatAB in other resistant clinical isolates showing efflux are currently 9 
under way. 10 
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FIGURE LEGENDS 5 
Figure 1 6 
Diffusion antibiograms of BB1013 in media with (A) and without (B) 10 µg/ml of 7 
reserpine. CIP, ciprofloxacin; NOR, norfloxacin; LEV, Levofloxacin; ENR, enrofloxacin. 8 
Numbers indicate the micrograms of antibiotic in the disc. 9 
 10 
Figure 2 11 
A. Genetic organization of smrA (left) and satAB (right) in S. suis strain ST3 12 
(upper lane), compared to their homologs in S. pneumoniae R6 (lower lane, stripped 13 
arrows). Open reading frames are shown by arrows, with the direction of transcription 14 
indicated by the arrowhead. 1, formamidopyrimidine-DNA glycosylase; 2, dephospho-15 
CoA kinase; 3, 50S ribosomal protein L33; 4, preprotein translocase subunit SecG; 5, 16 
exoribonuclease R; 6, UTP-glucose-1-phosphate uridylyltransferase; 7, glycerol-3-17 
phosphate dehydrogenase; 8, satR; 9, dUTP nucleotidohydrolase; 10, phosphoglycerate 18 
mutase; 11, DNA repair protein RadA; 12, arginyl tRNA synthase (argS) repressor; 13, 19 
DNA mismatch repair protein MutS; 14, degenerate transposase; 15, glutamine 20 
amidotransferase; *, hypothetical protein; and 16, glucose-6-phosphate isomerase. 21 
Numbers between the ORF’s show the percentage of identity between their products. B. 22 
Alignments of the promoter region of smrA and SatA and SatB from BB1001, BB1002 23 
  
33 
and BB1013. smrA: Canonical -35 box and RBS are highlighted with black boxes. Two 7 1 
bp inverted repeats (arrows) were found downstream the -35 box, separated by a 5 bp 2 
spacing region. in silico studies using SoftBerry Bprom software and the 133 bp 3 
immediately upstream smrA showed that the loss of two base pairs in the spacer region 4 
led to the recognition of a previously undetected -10 box immediately downstream the 3’ 5 
repeat (grey box). BB1013 bore three mutations when compared to FQ-susceptible 6 
strains. G-43A is located in the 3’ inverted repeat and could interfere with regulation of 7 
smrA expression. SatA and SatB: alignment of the amino acid sequence of SatA and SatB 8 
from the three strains. Conserved residues are represented in black over a white 9 
background. Light grey and dark grey backgrounds represent one and two differences 10 
among sequences respectively. 11 
 12 
Figure 3. 13 
Protein modeling of SmrA (A and B), SatA (C) and SatB (D). A. Lateral view of 14 
SmrA showing a 12 transmembrane segments structure typical of Major Facilitator 15 
Superfamily of transporters. Arrows show the amino acid substitutions present in 16 
BB1013 compared to BB1001 and BB1002. Red and yellow stained residues are T107A 17 
and I126V substitutions respectively. B. View down the channel of SmrA. C and D, 18 
modeling of SatA and B. A six transmembrane segments structure followed by a 19 
nucleotide-binding domain is observed in each protein. 20 
 21 
  
34 
Figure 4 1 
 Levels of expression of smrA and satAB in BB1013, compared to BB1001. 2 
Striped bars represent growth on subinhibitory concentrations of ciprofloxacin (1/4 of the 3 
MIC of each strain). Pump expression was normalized against rpoB expression levels. 4 
 5 
Figure 5 6 
A. Schematic representation of smrA and satAB integration in B. subtilis. Open 7 
reading frames are shown as arrows, with the direction of transcription indicated by the 8 
arrowhead. pDR67 bears regions of homology to the nonessential amyE locus of B. 9 
subtilis. These gene fragments are shown as broken arrows. Homologous recombination 10 
thereof with the chromosome allows for pDR67 integration. smrA and satAB amplicons 11 
were ligated to pDR67 and transformed directly in B. subtilis. B. Phenotypic screening of 12 
pDR67 integration in the chromosome. Bacteria are grown on LB containing 1% potato 13 
starch. Upper lane: B. subtilis 168 with a functional copy of amyE. Degradation of starch 14 
appears as a light unstained halo. Lower lane: BB1066, with pDR67 disrupting amyE, has 15 
no amylase activity. Starch is stained and no light zone is visible. 16 
 17 
Figure 6 18 
 Dendrograms from the amino acid sequence of SatA and SatB and closely related 19 
homologues of streptococci and enterococci. Trees were constructed with NCBI Blast by 20 
using Fast minimum evolution and Grishin parameters, and edited using MEGA software. 21 
The bar denotes genetic distance. A clear species-dependent clustering was observed 22 
among the hits obtained. Note, however, that (i) some S. mitis, S. oralis and S. 23 
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pneumoniae strains group mixed and that (ii) S. sanguinis strain ATCC 49296 clusters 1 
together with viridans streptococci, away from the 21 other members of this species 2 
represented by S. sanguinis SK49. Although this suggests a horizontal gene transfer 3 
event, it is rather a misidentification of S. sanguinis ATCC 49296 strain, as its 16S rRNA 4 
gene clusters with S. oralis and S. mitis too (data not shown), pointing to SatAB as a good 5 
evolutionary marker. To clearly illustrate this species-specific grouping, only one 6 
representative of each species is shown (with the number of strains included in each 7 
branch indicated by grey numbers), except for S. mitis and S. sanguinis, for which two 8 
strains have been represented and S. suis for which all non-redundant hits were included. 9 
It is noteworthy that SatB yields, in S. suis, one hit less than SatA. This is due to the fact 10 
that strain 05ZYH33 has an A1056 deletion in satB that leads to a premature STOP 11 
codon, rendering the identity with the query sequence too low to be represented in the 12 
tree. The similarity of both trees and the species specific clustering suggests the co-13 
evolution of both ORFs together and with the genome, and points to the non implication 14 
of satAB in horizontal gene transfer events.  15 
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TABLES 3 
TABLE 1. Strains and plasmids used in this study. 
Strains Relevant genotype Description Source or reference 
S. suis    
BB1001 Wild type Fluoroquinolone susceptible Escudero et al. (8) 
BB1002 Wild type  Fluoroquinolone susceptible Escudero et al. (8) 
BB1013 Wild type  Fluoroquinolone resistant. Efflux Escudero et al. (8) 
B. subtilis    
BS168 Reference strain. Used as recipient strain. Parental strain Courtesy Msadek, T. 
BB1066 amyE::PspaclacIΔlacZcat Control strain This work 
BB1067 amyE::PspacsmrABB1013lacIΔlacZcat  This work 
BB1068 amyE::PspacsatABBB1001lacIΔlacZcat Inducible resistance to NOR and CIP This work 
BB1069 amyE::PspacsatABBB1002lacIΔlacZcat Inducible resistance to NOR and CIP This work 
BB1070 amyE::PspacsatABBB1013lacIΔlacZcat Inducible resistance to NOR and CIP This work 
BB1071 amyE::PspacΔsatABBB1002lacIΔlacZcat  This work 
S. pneumoniae     
R6 Reference strain  Rockefeller Inst. 
BB1072 R6/pB1011 Control strain This work 
BB1073 R6/pB1012 Strain bearing smrABB1013 This work 
Plasmids    
pJS3 cat Replicative in Streptococcus spp. Ballester et al. (3) 
pJS3EB - EcoRI and BamHI restriction sites This work 
pB1011 pJS3EB:: PspaclacI Control plasmid This work 
pB1012 pJS3EB:: PspacsmrABB1013lacI Plasmid bearing smrABB1013 This work 
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Table 2. List of primers used in this study. 
Name Sequence 5′→3′ Reference 
Amplification and Sequencing   
satAF GTTGAGAACTTGTCCTAGGG This work 
satBR TGACCAGTTCGAATCCACGG This work 
smrAF ATGGCTGCTCAGCTTTCTTT This work 
smrAR AAACTAAAAGACTGTATTTTG This work 
Operon determination   
satAIntF CTGGTTTTGACAGAGAAGGG This work 
satBIntR CCGCAATGGCATTTCCAAGG This work 
Cloning in pDR67 and insert checking   
satAXbaIRBS GCGCTCTAGAGGTTAAACAGGTGGGCAATC This work 
satBBglIIStop GCGCAGATCTACTTTATTCAAACACAAACT This work 
smrAXbaIRBS GCTCTAGATTTTGGAGGAATTAAAGGAT This work 
smrABglIIR GCAGATCTTCACTACACATCCCTTACTT This work 
pDR67F ACATCCAGAACAACCTCTGC This work 
pDR67R CTCGTTTCCACCGAATTAGC This work 
Mobilisation to pJS3 and insert checking   
pJS3EcoRI GAACCGAATTCTCCTTTTTCGCTTC This work 
pJS3BamHI ATATGGATCCGGAGCTGTAATATAAAAAC This work 
pDR67EcoRI ATGAGAATTCTACACAGCCC This work 
pDR67BamHI CAGTGCAGGGATCCTAACTC This work 
pJS3InsF AATGTCACTAACCTGCCCCG This work 
pJS3InsR TGCCAAAAAGCTTCTGTAGG This work 
RT-Q-PCR   
smrARTF AAGCAGAATTTGAAGGTG This work 
smrARTR AAGGGCATTAACAGATACCG This work 
satABRTF AATCCAGAACCTTGTCAT This work 
satABRTR AATAATCATCCACCAGAGT This work 
rpoBsuisF AACTGGCGAGATCAAGAC This work 
rpoBsuisR AACGATGATACGCTCTGC This work 
rpoBBSF GGATGGCTACAACTATGAG This work 
rpoBBSR GCTTCTGATTCGTATTCTTC This work 
rpoB428 CGGTTGGTGAATTGCTTGCCAACC 4 
rpoB468R ACTGCAGCTGTTACAGGACGG 4 
Restriction sites are underlined 
 
 
 2 
 
 
 
Table 3. MIC in µg/ml of strains from this study against several fluoroquinolones. 
Ciprofloxacin  Norfloxacin  Enrofloxacin  Levofloxacin Strain Relevant Genotype 
- I IR  - I IR  - I IR  - I IR 
BB1066 No insert 0,06 0,06 0,06  0,25 0,25 0,12  0,06 0,06 0,06  0,12 0,12 0,12 
BB1067 smrA BB1013 0,06 0,06 0,06  0,25 0,25 0,12  0,06 0,06 0,06  0,12 0,12 0,12 
BB1068 satABBB1001 0,06 0,25 0,12  0,25 1 0,5  0,06 0,06 0,06  0,12 0,12 0,12 
BB1069 satABBB1002 0,06 0,25 0,12  0,5 2 0,5  0,06 0,06 0,06  0,12 0,12 0,12 
BB1070 satABBB1013 0,06 0,5 0,12  0,25 2 0,5  0,06 0,06 0,06  0,12 0,12 0,12 
BB1071 
ΔsatABBB1002 0,06 0,06 0,06  0,25 0,25 0,12  0,06 0,06 0,06  0,12 0,12 0,12 
-, standard media. I, 1mM IPTG added; IR, 1mM IPTG and 10 µg/ml of reserpine added.  






